Annual Report FY25 filed during CIRP, zero revenue, resolution plan approved
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kobo Biotech filed FY2024-25 annual report while under corporate insolvency resolution process (CIRP) since August 2024. NCLT admitted petition filed by JM Financial Asset Reconstruction Company. Board is suspended, Solapur plant remains shut. Revenue from operations is nil. Total income at Rs. 152 thousand. Loss after tax widened to Rs. 52.30 crore from Rs. 49.29 crore. NCLT approved a resolution plan from Beaufond Industries in May 2026, awaiting implementation. AGM on July 24, 2026 via video conference.
Company is insolvent with zero operations and widening losses. Resolution plan approval may enable revival, but existing shareholders likely face dilution or loss.